Quantcast
Last updated on April 23, 2014 at 15:23 EDT

Latest Endo Health Solutions Inc. Stories

2013-09-09 08:27:41

MALVERN, Pa., Sept. 9, 2013 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP), a U.S. based specialty healthcare company, announced today that it had appointed Suketu "Suky" Upadhyay as executive vice president and chief financial officer of Endo, effective September 23, 2013. "We are delighted to have Suky join the Endo team at this pivotal time," said Rajiv De Silva, president and chief executive officer of Endo. "He brings significant healthcare industry experience and...

2013-09-06 16:22:51

MALVERN, Pa., Sept. 6, 2013 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today announced that Rajiv De Silva, President and Chief Executive Officer, will present a corporate overview at the Stifel Nicolaus 2013 Healthcare Conference on Thursday, September 12, 2013 at 10:20 a.m. Eastern Time. A live webcast and audio archive of the presentation will be available on the company's website at www.endo.com. Click on Investor Relations, and then the link to the Event and...

2013-09-05 08:29:00

MALVERN, Pa., Sept. 5, 2013 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the complete response submission made by Endo to the new drug application (NDA) for its long-acting testosterone undecanoate injection, AVEED(TM), intended for men diagnosed with hypogonadism. In connection with the acceptance, the FDA assigned Endo's NDA a new...

2013-09-04 08:30:23

MALVERN, Pa. and RALEIGH, N.C., Sept. 4, 2013 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. (Nasdaq: ENDP), and BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today that the companies have completed interim analyses of both the opioid naive and opioid experienced Phase III trials for BEMA Buprenorphine. The interim analyses were conducted as part of the Phase III protocol to allow for adjustments to the sample size in order...

2013-08-28 08:26:34

MALVERN, Pa., Aug. 28, 2013 /PRNewswire/ -- -- Unique Generics Product Portfolio, Attractive Pipeline, Builds On Qualitest's Strength In Controlled Substances -- Transaction Expected To Be Immediately Accretive To Endo's Adjusted Diluted EPS -- Transaction Reflects Endo's Ongoing Transformation of Endo Into a Leading Specialty Healthcare Company Endo Health Solutions (NASDAQ: ENDP) today announced that its Qualitest subsidiary has reached a definitive...

2013-08-12 16:26:16

Metamark to Offer ProMark(TM) Prostate Cancer Prognostic Test Through Established Uropathology Lab with National Sales Force MALVERN, Pa. and CAMBRIDGE, Mass., Aug. 12, 2013 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today announced that its wholly owned subsidiary, HealthTronics, Inc. has entered into a definitive agreement to sell its anatomical pathology business, HealthTronics Laboratory Solutions, Inc., ("HLS") to Metamark Genetics, Inc. ("Metamark") for an undisclosed...

2013-08-12 08:30:08

LONDON, August 12, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Friday, August 9, 2013, the S&P 500 closed 0.36% lower at 1,691.42. Shares in drug manufacturing companies ended mostly lower as the broader market ended on a declining note. The major movers in the sector included Bristol-Myers Squibb Company (NYSE:BMY), Eli Lilly and Company (NYSE: LLY), Allergan Inc. (NYSE: AGN), and Endo Health Solutions...

2013-08-06 08:33:07

MALVERN, Pa., Aug. 6, 2013 /PRNewswire/ -- Total quarterly revenues of $767 million, decreased by 2 percent versus prior year. Second quarter reported diluted (GAAP) EPS of $0.30; Second quarter adjusted diluted EPS of $1.42 increased by 12 percent versus prior year. Company now expects 2013 revenues in the range of $2.70 billion to $2.80 billion. Company now expects reported diluted (GAAP) EPS in the range of $1.47 to $1.77; Company now expects 2013 adjusted diluted EPS in the...

2013-07-29 12:26:46

MALVERN, Pa., July 29, 2013 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) will announce its second quarter 2013 financial results before the open of the U.S. financial markets on August 6, 2013 and members of its senior management team will host a conference call and webcast at 8:30 a.m. ET that day to discuss these results. Investors and other interested parties may call 877-546-5019 (domestic) or 857-244-7551 (international) and enter passcode 83553344. Please dial in 10...

2013-07-22 08:29:16

MALVERN, Pa., July 22, 2013 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) today announced that it has appointed Don DeGolyer as Chief Operating Officer, Pharmaceuticals, which includes Endo Pharmaceuticals and Qualitest, effective August 1, 2013. "Don is a uniquely qualified, seasoned leader with nearly three decades of experience in the healthcare industry. Don has broad experience in both branded and generic pharmaceuticals and I have tremendous confidence in his...